<DOC>
	<DOCNO>NCT00939068</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety Telbivudine pregnancy prevention HBV perinatal transmission highly viraemic mother .</brief_summary>
	<brief_title>Efficacy Safety Study Telbivudine Prevent Perinatal Transmission</brief_title>
	<detailed_description>In present study , evaluate effect telbivudine give second third trimester pregnancy highly viremic , HBV DNA-positive mother maternal HBV DNA HBeAg level prior delivery rate vertical transmission HBV infant receive passive-active immunoprophylaxis . Additionally , investigate time administration telbivudine reduce risk perinatal transmission safety telbivudine pregnancy .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Telbivudine</mesh_term>
	<criteria>2040 year old pregnant woman gestational age 2032 week ; positive serum HBsAg ; HBV DNAâ‰¥1.0x106 copies/ml ; previous antiviral treatment ; clinical sign threaten miscarriage relate treatment early pregnancy ; positive serum HAV , HCV , HDV HEV test ; fetus deformity 3D ultrasound examination ; dug , immune modulators , cytotoxic drug steroid ; husband infect HBV .</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>Chronic hepatitis B , Telbivudine , Intrauterine transmission</keyword>
</DOC>